9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea-Reference-Cited by-同舟云学术

9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea

Published:2022-10 Issue:10362 Volume:400 Page:1522-1530
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Mok Jeongha,Lee Myungsun,Kim Deog Kyeom,Kim Ju Sang,Jhun Byung Woo,Jo Kyung-Wook,Jeon Doosoo,Lee Taehoon,Lee Ji Yeon,Park Jae Seuk,Lee Seung Heon,Kang Young Ae,Lee Jung-Kyu,Kwak Nakwon,Ahn Joong Hyun,Shim Tae Sun,Kim Song Yee,Kim Seungmo,Kim Kyungjong,Seok Kwang-Hyuk,Yoon Soyeong,Kim Young Ran,Kim Jisu,Yim Dahae,Hahn Seokyung,Cho Sang Nae,Yim Jae-Joon

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. Changes in treatment for multidrug-resistant tuberculosis according to national income;Kwak;Eur Respir J,2020

2. Clinical management of multidrug-resistant tuberculosis in 16 European countries;Günther;Am J Respir Crit Care Med,2018

3. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis;Lan;Lancet Respir Med,2020

4. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis;Van Deun;Am J Respir Crit Care Med,2010

5. A trial of a shorter regimen for rifampin-resistant tuberculosis;Nunn;N Engl J Med,2019

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid;Scientific Reports;2024-07-29

2. Timing and predictors of death during treatment in patients with multidrug/rifampin-resistant tuberculosis in South Korea;The Korean Journal of Internal Medicine;2024-07-01

3. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study;The Lancet Infectious Diseases;2024-06

4. QMAC-DST for Rapid Detection of Drug Resistance in Pulmonary Tuberculosis Patients: A Multicenter Pre–Post Comparative Study;Journal of Clinical Medicine;2024-05-16

5. Relapse after treatment with standardized all-oral short regimens for rifampicin-resistant tuberculosis (RR-TB): A systematic review and meta-analysis;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-05